Blossom, an excellent resource, with its tagline "Access our comprehensive database & reports to stay informed about the latest developments as psychedelics move from trials to treatments" has published a helpful recap of April's psychedelic research

This paper offers a first look at potential therapeutic mechanisms for AUD by reviewing the current literature on 5-MeO-DMT. Primarily, 5-MeO-DMT is able to induce mystical experiences and ego-dissolution together with increases in psychological flexibility and mindfulness.

The U.S. Drug Enforcement Administration is moving toward reclassifying marijuana as a less dangerous drug ... moving it from Schedule I to Schedule III.

We review research on the risks and benefits of psychedelics and discuss how the following depression treatments have shown decreasing effect sizes over time: (1) cognitive behavioral therapy, (2) mindfulness interventions, (3) selective serotonin reuptake inhibitors, and (4) ketamine. We speculate that a similar trend may occur for psychedelic treatments.

Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications.

This NOFO (Notice of Funding Opportunity) invites applications to support a clinical trials network involving multiple institutions to collect safety and early efficacy data of psychedelic-assisted therapy (PAT) in defined groups of older adults living with specific chronic pain conditions.  This NOFO uses the UG3 / UH3 Exploratory/Developmental Phased Award Cooperative Agreement activity code. Applications must include a research plan describing both UG3 and UH3 phases.

Inner healer scores were higher after the high versus placebo dose of psilocybin (t = 3.88, p < 0.001). Within the high-dose sub-sample only, inner healer scores predicted improved depressive symptomatology at 2 weeks post-dosing.  Conclusions: The principle of activating inner healing mechanisms via psychedelics is scientifically nascent; however, this study takes a positivist and pragmatic step forward, asking whether it warrants further examination.

Psychedelic music session playlists have been utilized consistently for modern psychedelic-assisted therapy clinical trials, and more recently researchers at Johns Hopkins University and Imperial College of London have specifically studied the effect of these music playlists on participants in trials.

These novel findings suggest that the influence of MDMA during the TE may carry protective effects into the peritraumatic period, possibly mediated through the known effects of MDMA in reducing negative emotions and elevating prosociality. These protective effects in turn may mitigate the development of early psychopathology-related symptoms.

In this meta-analysis, the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be tolerable and resolved within 48 hours. However, future studies need to more actively evaluate the appropriate management of adverse effects.

Cultural attitudes toward psychedelics are evolving due to promising research about their potential as mental health treatments. Without legal access to match the growing demand for these substances, consumers seek access through an unregulated underground market and may expose themselves to harm. Dispensaries offer a potential solution to this problem.

By the standard measures of drug safety, psychedelics are less dangerous than caffeine.  So, the risks must lie elsewhere.

As psychedelics are becoming increasingly available and research into their use in medicine advances, inclusion of relevant material in academic training programs will be essential to prepare future professionals to effectively educate and counsel patients.

Increasing psychological flexibility may be an important putative mechanism of change in psilocybin-assisted therapy for MDD and potentially, other mental health conditions.

In this narrative review, we focus on the evidence base for the effects of psilocybin on adult hippocampal neurogenesis and microglial form and function; which may suggest that psilocybin has the potential to modulate multiple mechanisms of action, and may have implications in altering the progression from major depression to dementia in those at risk.

Together, these findings provide a novel perspective on meditation and psychedelics that may reveal potential novel brain markers for positive synergistic effects between mindfulness practices and psilocybin.

This study shows a significant reduction in cluster attack frequency in a repeat round of pulse psilocybin administration and suggests that prior response may not predict the effect of repeated treatment.

A psychosocial measure of Communitas emerged as a predictor in older adults (OA), suggesting that the relational components in psychedelic group settings may hold particular value for OA.

For mothers with prenatal depression, a single low dose of esketamine after childbirth decreases major depressive episodes at 42 days post partum by about three quarters.

Conclusions Depression is common among individuals seeking CBMPs to treat PTSD and is associated with greater symptom severity and poorer quality of life. Effectiveness of CBMPs for treating PTSD does not appear to be impaired in people with comorbid depression.